Armata Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ARMP$3.75-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, | ||||||
| | 2025 | 2024 | ||||
| Operating activities: | | | | | | |
| Net loss | | $(6,531) | | $(25,021) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | | | | | | |
| Depreciation and amortization expense | | 377 | | 317 | ||
| Stock-based compensation expense | | | 781 | | | 534 |
| Change in fair value of the Convertible Loan | | | (5,203) | | | 13,025 |
| Non-cash interest expense | | | 3,596 | | | 1,815 |
| Non-cash interest income | | | — | | | (26) |
| Change in right-of-use asset | | | 597 | | | 464 |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other assets | | 539 | | 1,797 | ||
| Accounts payable and accrued liabilities | | (553) | | (1,488) | ||
| Accrued compensation | | | (933) | | | 180 |
| Operating lease liability | | | (250) | | | (2,181) |
| Net cash used in operating activities | | (7,580) | | (10,584) | ||
| Investing activities: | | | ||||
| Purchases of property and equipment | | | (99) | | | (250) |
| Net cash used in investing activities | | (99) | | (250) | ||
| Financing activities: | | | ||||
| Proceeds from issuance of term debt, net of issuance costs | | | 10,000 | | | 34,889 |
| Payments for taxes related to net share settlement of equity awards | | | (14) | | | — |
| Proceeds from exercise of stock options | | | — | | | 42 |
| Net cash provided by financing activities | | 9,986 | | 34,931 | ||
| Net increase in cash, cash equivalents and restricted cash | | 2,307 | | 24,097 | ||
| Cash, cash equivalents and restricted cash, beginning of period | | 14,771 | | 19,243 | ||
| Cash, cash equivalents and restricted cash, end of period | | $17,078 | | $43,340 | ||
| Supplemental disclosure of cash flow information: | | | ||||
| Unpaid debt issuance costs | | $— | | $26 | ||
| Property and equipment included in accounts payable and accrued liabilities | | | 9 | | | 425 |
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, | ||||||
| · · 2025 · 2024 | ||||||
| Cash and cash equivalents | | $11,688 | | $37,860 | ||
| Restricted cash | | | 5,390 | | | 5,480 |
| Cash, cash equivalents and restricted cash | | $17,078 | | $43,340 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.